Ads
related to: darzalex faspro patient information- DARZALEX® Side Effects
Find Information About Side Effects
Patients May Experience
- Cost Support Options
Learn About Potential Cost Support
Options Through Janssen CarePath
- About DARZALEX®
Learn About a Treatment Method and
How DARZALEX® Works
- Read Patient Stories
Learn About the Treatment Journey
From Real Patients & Caregivers
- Questions for Your Doctor
Find a List Of Questions for You to
Ask Your Healthcare Provider
- Sign Up for Support
Register With Janssen CarePath to
Receive Support Program Information
- DARZALEX® Side Effects
Search results
Results From The WOW.Com Content Network
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]
It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]
Genmab A/S announced on Jan. 15 that its drug, Darzalex Faspro has been approved by the US Food and Drug Administration (FDA) for the treatment of light-chain (AL) amyloidosis in adult patients ...
Amgen (AMGN) gets FDA nod for the label expansion of Kyprolis in combination with Darzalex Faspro and dexamethasone for treating patients with multiple myeloma at first or subsequent relapse.
AL amyloidosis is a rare disease; only 1200 to 3200 new cases are reported each year in the United States, and between 500 and 600 in the UK. Two thirds of patients with AL amyloidosis are male and less than 5% of patients are under 40 years of age. [6] [19] [9]
J&J (JNJ) submits sBLA seeking approval for Darzalex combination regimen in newly-diagnosed, transplant eligible multiple myeloma patient population
Ads
related to: darzalex faspro patient information